LATTICEFLOW-AI
1.2.2024 14:01:33 CET | Business Wire | Press release
LatticeFlow AI, the leading Artificial Intelligence (AI) platform for enabling enterprises to build performant, safe, and trustworthy AI systems at scale, today announced the appointment of Tom Ulrich as Senior Vice President and General Manager for North America. More recently, Tom served as Vice President of Sales, Financial Services at C3.AI, where he played a key role in launching the company’s AI banking business which led to a successful IPO in 2019 (NYSE:AI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201601542/en/
(Graphic: Business Wire)
Tom’s appointment follows LatticeFlow AI’s strategic expansion into the US market. With over 25 years of experience, Tom has proven expertise in building and developing world class sales teams for high-growth enterprise SaaS companies.
“Tom brings unmatched expertise in scaling early to mid-stage tech companies into hyper-growth phases. At LatticeFlow AI, Tom will play a vital role in accelerating our growth trajectory by identifying strategic business opportunities and driving revenue growth in the North American market,” said Petar Tsankov, CEO & Co-founder of LatticeFlow AI.
Earlier in his career, Tom held various sales leadership roles at MicroStrategy, where he helped grow the company from $20 million to $500 million, culminating in a successful IPO (NASDAQ:MSTR). Throughout his professional journey, Tom has remained steadfast in his dedication to helping clients unlock business value through data-driven insights.
"As AI becomes increasingly integral in our daily lives, ensuring model trust, safety, and a positive societal impact is more important than ever. I’m excited and honored to join the LatticeFlow AI team, collaborating with some of the best AI engineers in the world who are focused on tackling these challenges. I look forward to helping our customers harness the power of AI, while accelerating model performance and safety,” said Tom Ulrich.
“Tom joining LatticeFlow AI serves as yet another testimonial to the Company’s ability to attract world-class talent,” stated Andre Boisvert, Chairman of LatticeFlow AI. “Tom’s extensive experience in building global sales teams across five distinct enterprise software companies, with a particular focus on predictive analytics and AI, underscores his invaluable potential for propelling LatticeFlow AI's advancement.”
Tom received an MBA from George Washington University with a major in International Business and is based in Vienna, VA.
About LatticeFlow AI
Founded by world renowned AI researchers from ETH Zurich, LatticeFlow AI enables enterprise companies to develop production-ready machine learning models at scale. By systematically identifying and fixing model and data issues at scale, we help enterprises unlock the true potential of AI. Additionally, we offer a comprehensive technical AI assessment to assist enterprises achieve regulatory compliance, reliability and robustness for their mission-critical AI applications. LatticeFlow AI has won several awards including the AI Privacy Challenge in April 2023, followed by the Swiss AI Award and the US Army Global AI Award.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201601542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom